Tracheoesophageal Fistula from Carcinoma of the Esophagus

Symbas, Panagiotis N.; McKeown, Peter P.; Hatcher, Charles R.; Vlasis, S.E.

doi:10.1016/s0003-4975(10)62291-6

Cited by 22 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, few patients survive for more than 1 year. A review of the literature shows various treatments for ERF, although only a small number of studies have been conducted, and few data demonstrate the different characteristics of patients with or without ERF [4][5][6][7][8]. The primary purpose of this study was to determine the incidence, clinical presentation, and natural course of ERF in patients with esophageal cancer.…”

Section: Introductionmentioning

confidence: 99%

Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA)

et al. 2009

View full text Add to dashboard Cite

In this retrospective study, we investigated the incidence of esophagorespiratory fistula (ERF) in esophageal squamous cell carcinomas, clinical characteristics and outcomes of esophageal cancer patient with ERF, and effective therapeutic options. From 1998 to 2007, 1,095 patients with squamous cell carcinomas of the esophagus were treated at Samsung Medical Center. A comprehensive retrospective review of all these patients with clinical data of ERF was performed. The incidence of ERF in patients with esophageal cancer was 4.7% (52/1095). Comparing with the patients without ERF, the patients with ERF presented with a more advanced stage of disease, more frequent involvement of upper-mid thoracic esophagus, a longer segment of the tumor, and more initial airway involvement. The median time from the diagnosis of esophageal cancer to the development of a fistula was 7.9 months. ERF could be divided into three different categories according to the causes; (1) ERF associated with complication of the cancer progression (65.4%), (2) ERF related with treatments (28.8%), (3) ERF with mixed causes (5.8%). Four patients (8%) received radiation therapy, and nine patients (17%) underwent surgery to treat the ERF. Many of the patients with ERF were palliated with esophageal stent (40%) and/or gastrostomy (38%). The median survival time after diagnosis of the ERF was 8.0 weeks. An ERF resulting from esophageal cancer entails a poor prognosis in spite of supportive and/or definitive treatment. More comprehensive approach to improve the course of ERF and active supportive care, which can prevent complication from leakage, should be developed.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA)

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The total number of periprocedural deaths was 37, representing 15% mortality. Table 11 [1,6,[13][14][15]17,24,25] summarizes the data for 101 patients who underwent the enteric interposition procedure. The stomach or the colon were the usual organs used for bypassing the TEE The morbidity was remarkable for anastomotic leaks and disruptions (up to 30%) and combined perioperative mortality was 29% (29 patients).…”

Section: Methodsmentioning

confidence: 99%

“…A total of 45 patients underwent this procedure, of which there were 21 deaths for a mortality of 47%. The results of supportive care with or without an enterostomy are shown in Table IV [1,6,16,17,25]. A total of 170 patients received these modes of therapy.…”

Section: Methodsmentioning

confidence: 99%

Review: Malignant tracheo-esophageal fistula: Use of esophageal endoprosthesis

Spivak

Katariya

et al. 1996

J. Surg. Oncol.

View full text Add to dashboard Cite

“…It is not clear to what extent radiotherapy is responsible in the genesis of these fistulas [2,3]. Treat ment usually consists of local palliation with insertion of stents in the oesophagus or combined in the oesophagus and the tracheobronchial tree which seals the fistula and permits oral food intake.…”

Section: Introductionmentioning

confidence: 99%

Conservative Management of a Broncho-Oesophageal Fistula in a Patient with Non-Hodgkin’s Lymphoma

Zueger

Bolliger²,

Quadri³

et al. 1997

Respiration

View full text Add to dashboard Cite

We describe the case of a 56-year-old male patient with a 2-year history of productive cough and weight loss. The diagnosis of a broncho-oesophageal fistula due to a low-grade Non-Hodgkin’s lymphoma was made. The patient was referred for surgical closure of the fistula and resection of the left lower lobe because of intractable severe pneumonia. As an alternative treatment option, oesophageal or bronchial stent placement was considered. Because of the relatively favourable prognosis of this type of lymphoma, treatment with chemotherapy alone and a feeding gastrostomy were started. After eight cycles of cyclophosphamide and prednisone, the fistula healed spontaneously. Two years later, the patient continues to do well and is in remission. In patients with Non-Hodgkin’s lymphoma and an oesophagorespiratory fistula, treatment should first be conservative; surgery or stent placement should be postponed.

show abstract

Tracheoesophageal Fistula from Carcinoma of the Esophagus

Cited by 22 publications

References 6 publications

Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA)

Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA)

Review: Malignant tracheo-esophageal fistula: Use of esophageal endoprosthesis

Conservative Management of a Broncho-Oesophageal Fistula in a Patient with Non-Hodgkin’s Lymphoma

Contact Info

Product

Resources

About